Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3112689 | 0.81 | NUDT1 (0.41) | NUDT1L3MBTL1DYRK1A | |
| SCHEMBL325037 | 0.81 | CDK2 (0.43) | NUDT1 | |
| Hydrochloric Acid SCHEMBL31194792 | 0.79 | CDK2 (0.42) | NUDT1 | |
| SCHEMBL418310 | 0.71 | NUDT1 (0.46) | NUDT1L3MBTL1DYRK1A | |
| SCHEMBL1507164 | 0.69 | NUDT1 (0.45) | NUDT1L3MBTL1DYRK1A | |
| SCHEMBL1041231 | 0.69 | NUDT1 (0.45) | NUDT1L3MBTL1DYRK1A | |
| SCHEMBL2482390 | 0.69 | NUDT1 (0.45) | NUDT1L3MBTL1DYRK1A | |
| SCHEMBL3107190 | 0.69 | NUDT1 (0.45) | NUDT1L3MBTL1DYRK1A | |
| Hydrochloric Acid SCHEMBL8374910 | 0.69 | NUDT1 (0.56) | NUDT1L3MBTL1DYRK1A | |
| SCHEMBL9113922 | 0.69 | NUDT1 (0.45) | NUDT1L3MBTL1DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2029570-B1 | FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2014-10-15 | — | — | EP | disclosed |
| US-8324204-B2 | Fused thiophene derivatives as kinase inhibitors | UCB PHARMA SA (BE) | 2012-12-04 | — | — | US | disclosed |
| US-20100305066-A1 | Fused Thiophene Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305066-A1 | Fused Thiophene Derivatives as Kinase Inhibitors | PIKFYVE, PI4KA, PIK3CA | NUDT1 2721/4885L3MBTL1 1887/4885DYRK1A 464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.